Open fractures are debilitating injuries frequently complicated by infection and problems associated with wound and fracture healing.^[@r1]-[@r3]^ Their initial management includes thorough irrigation and debridement to remove debris and necrotic tissue.^[@r4]^ There has been uncertainty over the choice of irrigating pressure and solution on both the rate of complications and patients' health-related quality of life (HRQL) after open fractures.^[@r4]-[@r6]^ Used in conjunction with clinical outcomes, HRQL is highly relevant for the evaluation of fracture treatment and there has been an increase in its use in fracture trials.^[@r7]^

The Fluid Lavage in Open Fracture Wounds (FLOW) trial was a prospective, multicentre, randomized controlled trial that evaluated the effect of irrigation solution and pressure on rates of re-operation in 2447 adult patients.^[@r3],[@r8]^ Patients were randomized to one of three irrigating pressures: very-low pressure (1 psi to 2 psi), low pressure (5 psi to 10 psi), or high pressure (\> 20 psi), and one of two irrigating solutions: 0.45% solution of castile soap (Castile Soap, Triad Medical, Hartland and Aplicare Inc., Meriden, Connecticut) or sterile normal saline alone. The primary outcome was a composite of re-operation, defined as surgery within 12 months of the initial procedure to treat infection at the operative site, management of wound-healing problems and promotion of bone healing. The assessment of HRQL for 12 months post-fracture was an *a priori* planned part of statistical analysis.^[@r8]^In the current study, we aimed to determine: the impact of the composition of the irrigation solution and pressure of its delivery on HRQL and if patient HRQL returns to pre-fracture levels by 12-months post-fracture.

Patients and Methods
====================

FLOW trial
----------

Details of trial methodology and primary outcome results have previously been published.^[@r3],[@r8]^ Research Ethics Board approval for the trial was obtained at the co-ordinating centre (McMaster University) (REB: 08-268) and at each clinical site. The trial was prospectively registered at clinicaltrials.gov (NCT00788398).

HRQL
----

As a secondary outcome, patients enrolled in the FLOW study were asked to complete the 12-Item Short Form Health Survey (SF-12)^[@r9]^ and the EuroQol-5 Dimensions Questionnaire (EQ-5D)^[@r10]^ on recruitment to the trial (being asked to rate their pre-injury state), at two and six weeks, and at three, six, nine and 12-months post-injury.^[@r11]^

The SF-12 physical (PCS) and mental component scores (MCS) and EQ-5D index score were calculated according to the developers' recommendations. In our main analyses, we included patients where the SF-12 PCS, the SF-12 MCS or the EQ-5D score could be calculated for at least one follow-up visit between two weeks and 12 months.

Sample size
-----------

Sample size for the HRQL analysis was a factor in the development of the FLOW protocol.^[@r8]^ We considered an important difference in SF-12 to correspond to a moderate effect as described by Cohen^[@r12]^ and noted the minimally important difference in the SF-12 reported by Ware et al.^[@r9]^ In both cases, the value is 0.5 [sd]{.smallcaps}, equivalent to a five-point difference in the score. Specifying an α-level of 0.01 and a β-level of 0.20 (study power = 0.80), we required a sample of at least 405 patients (135 in each of three groups).

Initial sample size calculations for the EQ-5D were based on previous literature suggesting that a 0.03 to 0.04 incremental change in the Health Utilities Index (HUI)^[@r13]^ represents a patient-important difference,^[@r14]^ and that the EQ-5D correlates well with the HUI.^[@r15]^ We needed to recruit at least 329 patients in each of the three groups (α-level = 0.01, β = 0.20, difference = 0.04, σ = 0.15).

Data analysis
-------------

Our main analyses were based on multi-level generalized linear models, each comprising three levels (the clinical site, patient and time of HRQL assessment (i.e. visit)). We included the following independent variables: nature of the irrigation solution, pressure of irrigation, time point, baseline HRQL score and type of fracture (Gustilo type I/II vs. type III).^[@r16]^

Given that the FLOW trial evaluated both the pressure of and solution used for irrigation in the same patient population, we first ran the above model with an additional solution by a pressure interaction term, to identify any interaction between the two treatment factors. We planned *a priori* to remove from the model any interaction terms that were not significant.

Our final model for SF-12 PCS included the following independent variables: randomized solution, randomized pressure, time of HRQL assessment, pre-injury SF-12 PCS, fracture type and interaction of time of HRQL assessment by fracture type.

None of the interactions were significant in the analysis of the SF-12 MCS. The model therefore included: solution, pressure, time point, pre-injury SF-12 MCS and fracture type. The interaction of time point by fracture type was the only significant interaction term in the model for the EQ-5D. This model therefore included solution, pressure, time point, pre-injury EQ-5D score, fracture type and the interaction of time point by fracture type.

In addition to our main analysis, we performed an adjusted analysis that added factors to these models. These factors were: age, arm *versus* leg injury, postoperative fracture gap, initial method of internal fixation and severity of wound contamination.

We also conducted two *a priori* subgroup analyses for the SF-12 PCS, SF-12 MCS and EQ-5D scores, which were fracture type (Gustilo Type I or II *versus* Gustilo Type III);^[@r16]^ and fracture location (arm *versus* leg).

The mean scores and [sd]{.smallcaps}s for the SF-12 PCS, SF-12 MCS and EQ-5D were plotted over time by solution treatment group and pressure treatment group. Mean differences between the baseline (pre-injury) SF-12 PCS, SF-12 MCS and EQ-5D scores and the corresponding 12-month scores were calculated and compared using paired *t*-tests. A p-value \< 0.05 was considered statistically significant.

Patient demographics
--------------------

A total of 1860 patients were included, 1850 of whom completed the SF-12 and 1833 the EQ-5D. The patient demographics and injury characteristics are similar to the overall FLOW cohort (Table I).^[@r3]^ Mean age was 45.4 years ([sd]{.smallcaps} 17.6) and most (n = 1273, 68.4%) were men.

###### 

Patient characteristics and surgical and peri-operative management

                                                      **HRQL cohort, n = 1860**      **Total FLOW cohort, n = 2447**
  --------------------------------------------------- ------------------------------ ---------------------------------
  Mean age (yrs) ([sd]{.smallcaps})                   45.4 (17.6), n = 1860          45.2 (17.8)^\*^
  Gender, n (%)                                                                      
  Male                                                1273/1860 *(68.4)*             1680/2428 *(69.2)*
  Female                                              587/1860 *(31.6)*              748/2428 *(30.8)*
  Current smokers, n (%)                              614/1857 *(33.1)*              777/2405 *(32.3)*
  Work-related injuries, n (%)                        295/1859 *(15.9)*              349/2419 *(14.4)*
  **Mechanism of injury, n (%)**                                                     
  Motor vehicle accident (driver/passenger)           431/1860 *(23.2)*              613/2428 *(25.2)*
  Motor vehicle accident (pedestrian)                 197/1860 *(10.6)*              304/2428 *(12.5)*
  Motorcycle accident                                 330/1860 *(17.7)*              414/2428 *(17.1)*
  All-terrain vehicle accident                        42/1860 *(2.3)*                47/2428 *(1.9)*
  Crush injury                                        93/1860 *(5.0)*                116/2428 *(4.8)*
  Fall from standing                                  202/1860 *(10.9)*              261/2428 *(10.7)*
  Fall from height                                    352/1860 *(18.9)*              422/2428 *(17.4)*
  Twist                                               25/1860 *(1.3)*                26/2428 *(1.1)*
  Direct trauma (penetrating)                         64/1860 *(3.4)*                74/2428 *(3.0)*
  Direct trauma (blunt)                               117/1860 *(6.3)*               141/2428 *(5.8)*
  Explosion                                           1/1860 *(0.1)*                 2/2428 *(0.1)*
  Bicycle accident                                    5/1860 *(0.3)*                 6/2428 *(0.2)*
  Plane crash                                         1/1860 *(0.1)*                 1/2428 *(0.04)*
  Other                                               0/1860 *(0.0)*                 1/2428 *(0.04)*
  **Major concomitant trauma, n (%)**                                                
  Head injury                                         103/1860 *(5.5)*               145/2429 *(6.0)*
  Chest injury                                        124/1860 *(6.7)*               187/2429 *(7.7)*
  Intra-abdominal injury                              67/1860 *(3.6)*                95/2429 *(3.9)*
  Any of the above                                    233/1860 *(12.5)*              328/2429 *(13.5)*
  **Gustilo Type, n (%)**                                                            
  Type I                                              463/1857 *(24.9)*              639/2419 *(26.4)*
  Type II                                             703/1857 *(37.9)*              899/2419 *(37.2)*
  Type IIIA                                           526/1857 *(28.3)*              649/2419 *(26.8)*
  Type IIIB                                           165/1857 *(8.9)*               232/2419 *(9.6)*
  **Location of fracture, n (%)**                                                    
  Arm                                                 554/1860 *(29.8)*              758/2428 *(31.2)*
  Leg                                                 1306/1860 *(70.2)*             1670/2428 *(68.8)*
  Hours to first incision from injury, median (IQR)   10.0 (6.4 to 15.9), n = 1832   9.8 (6.4 to 15.9), n = 2374
  **Surgical preparation solution, n (%)**                                           
  Iodine or providone-iodine                          1000/1852 *(54.0)*             1394/2413 *(57.8)*
  Chlorhexidine                                       930/1852 *(50.2)*              1100/2413 *(45.6)*
  Alcohol                                             294/1852 *(15.9)*              436/2413 *(18.1)*
  Other                                               11/1852 *(0.6)*                14/2413 *(0.6)*
  **Definitive fixation, n (%)**                                                     
  Intramedullary nail                                 635/1860 *(34.1)*              821/2422 *(33.9)*
  External fixator                                    33/1860 *(1.8)*                59/2422 *(2.4)*
  Plate                                               962/1860 *(51.7)*              1218/2422 *(50.3)*
  Other internal fixation                             221/1860 *(11.9)*              308/2422 *(12.7)*
  Other                                               9/1860 *(0.5)*                 16/2422 *(0.7)*

\*the ages of four patients in the FLOW cohort were not known. Mean age was calculated with n = 2443

HRQL, health-related quality of life; FLOW, Fluid Lavage in Open Fracture Wounds; IQR, interquartile range

Results
=======

Most patients had a leg injury (n = 1306, 70.2%) and underwent definitive fixation with a plate (n = 962, 51.7%) or intramedullary nail (n = 635, 34.1%).

HRQL by irrigation pressures and solutions
------------------------------------------

We did not find any significant differences in SF-12 PCS, SF-12 MCS or EQ-5D utility scores between soap and saline or between the three irrigation pressure groups over the one-year follow-up period (Figs 1 to 3). Our adjusted analyses did not show any significant differences when compared with the main analyses, so unadjusted analyses are presented. We did not find subgroup effects on any outcome measure of fracture type or location.

![Short Form (SF)-12 scores (physical component score (PCS) and mental component score (MCS)) over time by solution.](BJJ-2017-0955.R1-galleyfig1){#f1}

![Short Form (SF)-12 scores (physical component score (PCS) and mental component score (MCS)) over time by pressure.](BJJ-2017-0955.R1-galleyfig2){#f2}

![EuroQol-5 Dimensions (EQ-5D) utility scores over time by solution and by pressure.](BJJ-2017-0955.R1-galleyfig3){#f3}

In our analysis of the SF-12 PCS, we found a significant interaction (p = 0.032) between solution and pressure. As both variables had been included in the same model, we also included interaction terms between solution and time, and between pressure and time. In this model, the interaction was still significant (p = 0.032) but the interactions between time point and solution, and between time point and pressure were not significant (p = 0.88 and p = 0.54, respectively).

In order to evaluate the magnitude and nature of the interaction between pressure and solution, we examined the effect of solution within each level of pressure, and the effect of pressure within each level of solution (Table II). Since this interaction was an unexpected finding, we sought to objectively evaluate its credibility. We elected to adapt criteria that have previously been used to assess the credibility of a sub-group analysis^[@r17]^ to determine if our observed interaction was believable. Based upon the application of these criteria, we determined that this finding had low credibility (Table III).

###### 

Effect of treatment group on Short Form-12 physical component scores (PCS) at 12 months

                             **Mean difference between 12-month PCS (95% CI)**^\*^
  -------------------------- -------------------------------------------------------
  **At high pressure**       
  Soap *vs* saline           1.18 (0.02 to 2.33)
                             
  **At low pressure**        
  Soap *vs* saline           0.45 (-0.71 to 1.61)
                             
  **At very low pressure**   
  Soap *vs* saline           -0.99 (-2.16 to 0.18)
                             
  **With soap**              
  High *vs* low              -0.12 (-1.28 to 1.04)
  High *vs* very low         0.51 (-0.64 to 1.67)
  Low *vs* very low          0.63 (-0.53 to 1.79)
                             
  **With saline**            
  High *vs* low              -0.84 (-2.00 to 0.31)
  High *vs* very low         -1.65 (-2.82 to -0.48)
  Low *vs* very low          -0.81 (-1.98 to 0.36)

^\*^from the main 3-level model

CI, confidence interval

###### 

Assessment of credibility of interaction between pressure and solution for Short Form (SF)-12 physical component scores (PCS**)**

  **Criteria**^\*^                                                                                        **Assessment**
  ------------------------------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Is the interaction variable a characteristic measured at baseline or after randomization?               Measured at the time of randomisation
  Is the effect suggested by comparisons within rather than between studies?                              Yes, it is suggested by comparisons within a single study rather than between studies
  Was the hypothesis specified *a priori*?                                                                Our *a priori* hypothesis was that there would be an interaction between pressure and solution
  Was the direction of the interaction effect specified *a priori*?                                       We were unable to find a compelling reason to specify a direction of a possible effect modification
  Was the interaction effect one of a small number of hypothesized effects tested?                        We looked at the following three interactions: randomized solution with randomized pressure, randomized solution with time of HRQL assessment and randomized pressure with time of HRQL assessment
  Does the interaction test suggest a low likelihood that chance explains the apparent subgroup effect?   We obtained p = 0.032 for the interaction term, which suggests a low likelihood that chance explains the apparent effect
  Is the significant interaction effect independent?                                                      The interaction was not influenced by the inclusion of other interaction terms in the analysis
  Is the size of the interaction effect large?                                                            No, the size of the effect is less than half of the minimum clinically important difference for the SF-12 PCS
  Is the interaction consistent across studies?                                                           Not applicable, as no other studies have evaluated this interaction
  Is the interaction consistent across closely related outcomes within this study?                        No, this interaction was not observed for the SF-12 MCS or the EQ-5D index score. Also, no interaction was observed between pressure and solution for the primary study outcome of reoperation within 12 months
  Is there indirect evidence that supports the hypothesized interaction (biological rationale)            No, there is no biological rationale for the observed interaction

\*Adapted from criteria developed to evaluate the credibility of subgroup analyses^[@r17],[@r18]^

HRQL, health-related quality of life; EQ-5D, EuroQol-5 Dimensions

HRQL at one-year post-injury
----------------------------

One year post-injury, most patients had not regained their pre-injury HRQL by any of the three outcome measures (p \< 0.001). Patients' mean SF-12 PCS at one year was 10.01 (95% confidence interval (CI) 9.38 to 10.64) points lower than their pre-injury score, and their mean SF-12 MCS was 2.61 (95% CI 1.97 to 3.25) points lower than prior to injury. Patients' EQ-5D mean utility scores were 0.15 (95% CI 0.14 to 0.16) lower than pre-injury. At one year, patients had returned to 81% of their PCS, 95% of their MCS and 84% of their ED-5D utility score.

Discussion
==========

We found no differences between irrigation pressures in the SF-12 PCS, SF-12 MCS and EQ-5D utility score. This echoes the findings of our primary study. Analysis of the SF-12 and the EQ-5D did not capture the difference between the composition or pressure of the delivery system for the irrigation solutions which was seen in our primary study. This may have been because the outcome measures were not sufficiently responsive to capture the relatively small differences in HRQL resulting from only 41 more patients undergoing re-operation in the soap group when compared with the saline group.

In our analysis of the SF-12 PCS, the significant interaction (p = 0.032) between solution and pressure was unexpected, given that the initial FLOW analysis had found no such interaction. The size of the interaction was relatively small, constituting less than half of the minimum important difference of five points for the SF-12 PCS. No such interaction was seen with the SF-12 MCS, for the EQ-5D utility score, or in the re-operation rate in the original study. There is no basic scientific rationale to support the existence of such an interaction. Consequently, based on the application of the adapted criteria, we concluded that the observed interaction was not highly plausible, and was most likely a spurious finding.

We found that patients with open fractures had not returned to their pre-injury status at one-year post-injury. This is in keeping with the results of the Study to Prospectively Evaluate Reamed Intramedullary Nails in Tibial Fractures (SPRINT) trial, which also reported a reduction of 10 points in the PCS of the SF-36 over the same time period in open and closed tibial fractures.^[@r19]^ The EQ-5D scores were 0.15 points lower at one year, which also represents a clinically important difference.^[@r11]^ The SF-12 MCS, by contrast, was 2.66 points lower and hence not a clinically important difference. These findings are also consistent with the results of the SPRINT trial, which found the SF-36 MCS to be approximately 2 points lower at one year.^[@r19]^ Similarly, a recent study of functional recovery in patients with tibial fracture reported that HRQL had not returned to baseline at one year or at five years post-injury.^[@r20]^ Several other studies in the literature reflect this.^[@r21]-[@r23]^

A strength of our study is its large, multicentre, randomized controlled nature, with a sample size that exceeds the *a priori* calculation, and its use of standardized, validated outcome measures. This is one of the largest studies to date of its kind and the inclusion of over 40 clinical sites in five countries increases the ability to generalize from our results.

Despite these strengths, our study has several limitations. The method of recording pre-injury quality of life may be prone to recall bias, although previous research has suggested that the level of bias is minimal.^[@r24]^ We did not include any anatomical- or disease-specific outcome measures; typically, these do not provide such granular data on the global effect on HRQL and add a significant documentation burden to a trial enrolling patients with potentially diverse patterns of injury. This can, in turn, affect recruitment and retention rates.

This study may also be limited by its follow-up. Although one year is a frequently used follow-up period in fracture research, it may be insufficient to evaluate recovery fully. We were able to include 76% of patients enrolled in the FLOW study in this analysis; while this demonstrates a not insignificant loss to follow-up, this is a comparable proportion with that seen in previous orthopaedic trauma trials.^[@r19]^

These results show that neither irrigation pressure nor the composition of the solution have an effect on patients' HRQL within 12 months of open fracture. Despite modern fracture implants and high-quality care, patients are not returning to pre-injury status within 12 months. This can guide both surgeon and patient expectations after open fracture. It also suggests that factors other than surgical treatment may be important, and that non-surgical interventions may be necessary to help patients recover.

Future research needs to look beyond surgical technique and consider the influence of psychological support, social circumstances and co-morbidity on outcome. Although generic measures detected decrements in HRQL at one year, they may not be sufficient to capture the much smaller differences in clinically important outcomes in open fracture trials. Future methodological research is needed to understand better the assessment of HRQL in patients with open fractures.

**Take home message:**

\- Irrigation solution and irrigation pressure do not have an effect on 12-month post-open fracture HRQL.

\- Despite the use of modern fracture implants and high-quality surgical care, patients sustaining open fractures do not return to their pre-injury HRQL at 12 months post-injury.
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